Please provide your email address to receive an email when new articles are posted on . Care for COPD has consisted of combinations of previously used drugs for decades. Ensifentrine represents a ...
Opinions expressed by Digital Journal contributors are their own. As healthcare systems worldwide continue to address the effects of the COVID-19 pandemic, pharmaceutical companies like Amneal ...
Advances in lung cancer treatment have changed survival in ways that were unimaginable even a decade ago. Targeted drugs, ...
Indian pharma juggernaut Lupin—best known in the U.S. for its portfolio of generic drugs—is laying down new manufacturing roots in Florida. Lupin expects to invest a combined $250 million—covering R&D ...
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum ...
Veru knows the route that its once-dismissed respiratory distress drug has to take to pacify regulators, but the biotech needs some more cash to hit the road. That’s according to the company’s latest ...
Feb 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and ...
AstraZeneca has sold U.S. rights to its treatment for infant lung infections to Swedish Orphan Biovitrum for $1.5 billion, the latest move by the drugmaker to trim its pipeline and refocus on priority ...
NEW YORK, June 27 (Reuters) - Merck & Co Inc and Schering-Plough Corp said on Friday they withdrew their U.S. application for combining their blockbuster allergy drugs Singulair and Claritin into one ...
HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback